

# Ben-Quan Shen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6326507/publications.pdf>

Version: 2024-02-01

15  
papers

626  
citations

933447

10  
h-index

996975

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

773  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody-Drug Conjugates in Rats. <i>Bioconjugate Chemistry</i> , 2011, 22, 1994-2004.	3.6	177
2	Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism. <i>Current Drug Metabolism</i> , 2012, 13, 901-910.	1.2	116
3	Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. <i>MAbs</i> , 2011, 3, 376-386.	5.2	84
4	A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody-Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer. <i>AAPS Journal</i> , 2014, 16, 994-1008.	4.4	72
5	Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. <i>British Journal of Pharmacology</i> , 2012, 166, 368-377.	5.4	39
6	Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 82, 1-13.	2.7	33
7	Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates. <i>Bioanalysis</i> , 2015, 7, 1583-1604.	1.5	28
8	Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates. <i>Methods in Molecular Biology</i> , 2013, 1045, 117-131.	0.9	17
9	Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia. <i>MAbs</i> , 2018, 10, 1312-1321.	5.2	13
10	Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice. <i>MAbs</i> , 2014, 6, 1631-1637.	5.2	12
11	Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVYA®) Antibody-Drug Conjugate in Sprague Dawley Rats. <i>Journal of Clinical Medicine</i> , 2021, 10, 1323.	2.4	10
12	Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 303-317.	2.5	10
13	Characterization of Tissue Distribution, Catabolism, and Elimination of an Anti- <i>Staphylococcus aureus</i> THIOMAB Antibody-Antibiotic Conjugate in Rats. <i>Drug Metabolism and Disposition</i> , 2020, 48, 1161-1168.	3.3	9
14	Anti-Lymphocyte Antigen 6 Complex, Locus E-Seco-Cyclopropabenzindol-4-One-Dimer Antibody-Drug Conjugate That Forms Adduct with $\pm$ 1-Microglobulin Demonstrates Slower Systemic Antibody Clearance and Reduced Tumor Distribution in Animals. <i>Drug Metabolism and Disposition</i> , 2020, 48, 1247-1256.	3.3	3
15	Complex formation of anti-VEGF with VEGF released during blood coagulation resulted in an artifact in its serum pharmacokinetics. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00573.	2.4	3